We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
- Authors
RATZIU, V.; GIRAL, P.; MUNTEANU, M.; MESSOUS, D.; MERCADIER, A.; BERNARD, M.; MORRA, R.; IMBERT‐BISMUT, F.; BRUCKERT, E.; POYNARD, T.
- Abstract
Background Mortality related to complications of cirrhosis is increasing in patients with insulin-resistance factors. Hyperlipidaemic patients have multiple risk factors of insulin resistance. It is impossible to perform liver biopsy in such a large number of hyperlipidaemic patients to identify patients with advanced liver fibrosis or with steatohepatitis (non-alcoholic steatohepatitis, NASH). Aims To use the non-invasive biomarkers, FibroTest (FT), SteatoTest and NashTest, and to assess the prevalence of advanced liver disease in a large population of hyperlipidaemic patients. Methods A consecutive cohort of hyperlipidaemic patients was followed prospectively in a lipid centre and the sera were analysed retrospectively. Results A total of 2834 subjects were included: 1909 hyperlipidaemic patients and 925 blood donors (BD). Advanced fibrosis was identified by FT in 53/1909 (2.8%) hyperlipidaemic patients vs. 0/925 BD (0%) ( P < 0.0001); advanced steatosis in 569/1893 hyperlipidaemic patients (30.1%) vs. 8/164 (4.9%) BD ( P < 0.0001) and NASH in 132/1893 (7%) vs. 0/164 (0%), respectively ( P < 0.0001). There was a highly significant and linear association between the number of metabolic syndrome factors and liver disease prevalence – the highest being for type 2 diabetics: advanced steatosis 66%, NASH 24% and advanced fibrosis 6%. Conclusions The prevalence of fibrosis, steatosis and NASH in hyperlipidaemic patients appears to be high (3%, 30% and 7%, respectively). Biomarkers could be useful for screening of advanced fibrosis and NASH in patients with several metabolic syndrome factors, to prevent liver mortality.
- Subjects
BIOMARKERS; MEDICAL screening; LIVER diseases; HYPERLIPIDEMIA; DEATH rate; METABOLIC syndrome; DIAGNOSIS
- Publication
Alimentary Pharmacology & Therapeutics, 2007, Vol 25, Issue 2, p207
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2006.03182.x